

Estimation of Malondialdehyde, Total Antioxidant Capacity, and Selenium Levels in Serum of Intractable Epileptic Children Receiving Treatment with Ketogenic Diet

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Pediatrics*

By

Sarah Abd Elaziz Kamel Dawh

(M.B.B.Ch, 2012)

Under Supervision of

Prof. Omnia Fathy Alrashidy

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Prof. Mai Mahmoud Youssef

Professor Researcher

Child Health Departement-National Research Center

Dr. Yasmin Gamal Abdo Elgendy

Lecturer of Pediatrics

Faculty of Medicine- Ain Shams University

Faculty of Medicine

Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

First of all, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

Really I can hardly find the words to express my gratitude to **Prof. Dr Omnia Fathy El-Rashidy**, Professor of Pediatrics, Faculty of Medicine - Ain Shams University, for her supervision, continuous help, encouragement throughout this work and tremendous effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.

I would like also to express my sincere appreciation and gratitude to **Prof Dr. Mai Mahmoud Youssef**, Professor Researcher, Child Health department, National Research Center, for her continuous directions and support throughout the whole work.

I cannot forget the great help of **Dr. Yasmin Gamal El-gendy**, Lecturer of Pediatrics, Faculty of Medicine -Ain shams University, for her invaluable efforts, tireless guidance and for her patience and support to get this work into light.

I express my warm thanks to **Prof DR, Manal Mohsen**, Prof Researcher, Child Health Department, National Research Center, for sharing expertise, and sincere and valuable guidance and encouragement throughout the whole work.

My sincere thanks also goes to **Assis. Prof Dr. Safaa Metwally Morsy**, Professor of Bio-chemistry, Medical Bio-chemistry Department, National Research Center, who gave me access to the laboratory and research facilities. Without her precious support it would not be possible to conduct this research.

Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward, this work would not have ever been completed.

List of Contents

Title	Page No.
List of Tables	5
List of Figures	8
List of Abbreviations	10
Introduction	1
Aim of the Study	18
Review of Literature	
▪ Epilepsy	19
▪ Ketogenic Diet	32
▪ Selenium	49
▪ Oxidative Stress	58
Subjects and Methods	68
Results	79
Discussion	106
Summary	117
Conclusion	120
Recommendations	121
References	122
Appendix	148
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Changes in seizure type classification from 1981 to 2017	22
Table (2):	Electroclinical syndromes and other epilepsies	24
Table (3):	A proposed diagnostic scheme for people with epileptic seizures and with epilepsy	26
Table (4):	Potential uses of KD in various illnesses (clinical and laboratory studies)	33
Table (5):	Composition of the KDs and its variants	34
Table (6):	Contraindications of KD	46
Table (7):	RDA and UL in $\mu\text{g/day}$ for Se as set forth by Germany, Austria and Switzerland , Nordic countries (Denmark, Finland, Iceland, Norway, Sweden, Faroe Islands, Greenland, Åland) New Zealand (NZ) and Australia (AUS), the USA, and the United Kingdom (UK)	56
Table (8):	Antioxidant molecules in experimental studies	64
Table (9):	Procedure of TAC estimation in serum sample	74
Table (10):	Description of personal, demographic and clinical data among refractory epileptic cases without KD (group I)	80
Table (11):	Description of etiology of seizures among refractory epileptic cases without KD (group I)	81
Table (12):	Description of types of seizures among refractory epileptic cases without KD (group I)	81
Table (13):	Description of anthropometric measures among refractory epileptic cases without KD (group I)	81

List of Tables (cont...)

Table No.	Title	Page No.
Table (14):	Description of serum Se ($\mu\text{g/l}$), TAC (mm/L) and MDA (nmol/l) among refractory epileptic cases without KD (group I).....	82
Table (15):	Description of 24 hr recall analysis among refractory epileptic cases without KD (group I)	83
Table (16):	Description of personal, demographic and clinical data among refractory epileptic cases on KD (group II).....	84
Table (17):	Description of etiology of epilepsy among refractory epileptic cases on KD (group II)	85
Table (18):	Description of types of seizures among refractory epileptic cases on KD (group II)	85
Table (19):	Description of anthropometric measures among refractory epileptic cases on KD (group II)	86
Table (20):	Description of serum Se ($\mu\text{g/l}$), TAC (mm/l) and MDA (nmol/l) among refractory epileptic cases on KD group II.....	86
Table (21):	Description of 24 hr recall analysis among refractory epileptic cases on KD group II	87
Table (22):	Comparison between three study groups as regard personal and demographic data.....	88
Table (23):	Comparison between group I and II as regard etiology of seizures:.....	89
Table (24):	Comparison between group I and II as regard types of seizures:	90
Table (25):	Comparison between three study groups as regard anthropometric measures	91
Table (26):	Comparison group I and group II as regard age of onset of epilepsy, seizure freq/w and Chalfont score:	92

List of Tables (cont...)

Table No.	Title	Page No.
Table (27):	Comparison between three study groups as regard serum Se ($\mu\text{g/l}$), TAC (mm/l) and MDA (nmol/l).....	93
Table (28):	Comparison between three study groups as regard 24 hr recall analysis	95
Table (29):	Correlations between serum Se ($\mu\text{g/l}$), TAC (mm/l) and MDA (nmol/l) among the 3 studied groups.....	97
Table (30):	Correlations between serum Se ($\mu\text{g/l}$) and frequency of fits/wk among group I and group II.....	99
Table (31):	Correlations between TAC (mm/l) and frequency of fits per week among group I and group II.....	100
Table (32):	Correlations between MDA (nmol/l) and frequency of fits per week among group I and group II.....	102
Table (33):	Relation between number of drugs and serum Se ($\mu\text{g/l}$), TAC (mm/l) and MDA (nmol/l) among refractory epileptic cases without KD (group I).....	104
Table (34):	Relation between number of drugs and serum Se ($\mu\text{g/l}$), TAC (mm/l) and MDA (nmol/l) among refractory epileptic cases on KD (group II).....	105

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	ILAE classification of seizure types expanded form	22
Fig. (2):	Framework for classification of the epilepsies	23
Fig. (3):	Formation of ketone bodies	35
Fig. (4):	Structure of GABA	37
Fig. (5):	Metabolic modifications of glutamate and GABA synthesis	39
Fig. (6):	Potential pathways through which polyunsaturated fatty acids (PUFAs) may limit hyperexcitability in the brain	42
Fig. (7):	Organic forms of selenium	50
Fig. (8):	Basics of ROS enzymatic control	61
Fig. (9):	Comparison between three study groups as regard serum Se ($\mu\text{g/l}$), TAC (mm/l) and MDA (nmol/l)	93
Fig. (10):	Comparison between three study groups as regard CHO, lipid and protein intake in 24 hr recall analysis	95
Fig. (11):	Correlations between serum Se ($\mu\text{g/l}$), TAC (mm/l) among refractory epileptic cases on KD (group II)	98
Fig. (12):	Correlations between serum Se ($\mu\text{g/l}$) and MDA (nmol/l) among refractory epileptic cases on KD (group II)	98
Fig. (13):	Correlations between serum Se ($\mu\text{g/l}$) and frequency of fits/wk among refractory epileptic cases without KD (group I)	99
Fig. (14):	Correlations between serum Se ($\mu\text{g/l}$) and frequency of fits per week among refractory epileptic cases on KD (group II)	100

List of Figures (cont...)

Fig. No.	Title	Page No.
Fig. (15):	Correlations between TAC (mm/l) and frequency of fits per week among refractory epileptic cases without KD (group I).....	101
Fig. (16):	Correlations between TAC (mm/l) and frequency of fits per week among refractory epileptic cases on KD (group II).....	101
Fig. (17):	Correlations between MDA (nmol/l) and frequency of fits per week among refractory epileptic cases without KD (group I).....	102
Fig. (18):	Correlations between MDA (nmol/l) and frequency of fits per week among refractory epileptic cases on KD (group II).....	103

List of Abbreviations

Abb.	Full term
<i>AA</i>	<i>Arachidonic acid</i>
<i>AcAc</i>	<i>Aceto-acetate</i>
<i>ADEAF</i>	<i>Autosomal dominant epilepsy with auditory features</i>
<i>ADNFLE</i>	<i>Autosomal-dominant nocturnal frontal lobe epilepsy</i>
<i>AED</i>	<i>Anti-epileptic drugs</i>
<i>ATP</i>	<i>Adenosine triphosphate</i>
<i>BDH1</i>	<i>Bidirectional BHB dehydrogenase</i>
<i>BECTS</i>	<i>Benign epilepsy with centrotemporal spikes</i>
<i>BFNE</i>	<i>Benign familial neonatal epilepsy</i>
<i>BHB</i>	<i>Hydroxy- Butarate</i>
<i>BNS</i>	<i>Benign neonatal seizures</i>
<i>Ca²⁺</i>	<i>Calcium</i>
<i>CAE</i>	<i>Childhood absence epilepsy</i>
<i>CBZ</i>	<i>Carbamazepine</i>
<i>CPT</i>	<i>Carnitine palmitoyltransferase</i>
<i>CSWS</i>	<i>Continuous spike-and-wave during sleep</i>
<i>Cu / Zn</i>	<i>Copper-zinc</i>
<i>DHA</i>	<i>Docosahexanoic acid</i>
<i>ECSOD</i>	<i>Extracellular superoxide dismutase</i>
<i>EEG</i>	<i>Electroencephalogram</i>
<i>EME</i>	<i>Early myoclonic encephalopathy</i>
<i>ESES</i>	<i>Electrical Status Epilepticus during Slow Sleep</i>
<i>FS</i>	<i>Febrile seizures</i>
<i>GABA</i>	<i>Gamma-amino butyric acid</i>
<i>GLUT-1</i>	<i>Glucose transporter type 1</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>GPx</i>	<i>Glutathione Peroxidase</i>
<i>GSH</i>	<i>Glutathione</i>
<i>GTC</i>	<i>Generalized tonic clonic</i>
<i>H₂O₂</i>	<i>hydrogen peroxide</i>
<i>HMG-CoA</i>	<i>3-hydroxy-3-methylglutaryl CoA</i>
<i>HS</i>	<i>Highly significant</i>
<i>ILAE</i>	<i>International League Against Epilepsy</i>
<i>IQR</i>	<i>Interquartile range</i>
<i>JME</i>	<i>Juvenile myoclonic epilepsy</i>
<i>KA</i>	<i>Kainic acid</i>
<i>KD</i>	<i>Ketogenic diet</i>
<i>LCAD</i>	<i>Long-chain acyl dehydrogenase deficiency</i>
<i>LCT</i>	<i>Long chain triglyceride</i>
<i>LEV</i>	<i>Levetiracetam</i>
<i>LGIT</i>	<i>Low Glycemic Index Treatment</i>
<i>LKS</i>	<i>Landau-Kleffner syndrome</i>
<i>LMT</i>	<i>Lamotrigine</i>
<i>MAD</i>	<i>Modified Atkins diet</i>
<i>MCAD</i>	<i>Medium-chain acyl dehydrogenase deficiency</i>
<i>MCT</i>	<i>Medium chain triglyceride</i>
<i>MDA</i>	<i>Malonylaldehyde</i>
<i>MEG</i>	<i>Magneto-encephalography</i>
<i>MEI</i>	<i>Myoclonic epilepsy in infancy</i>
<i>MERF</i>	<i>Myoclonic epilepsy with ragged red fibers</i>
<i>Mn</i>	<i>Manganese</i>
<i>mtDNA</i>	<i>Mitochondrial DNA</i>
<i>MTLE with HS</i>	<i>Mesial temporal lobe epilepsy with hippocampal sclerosis</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>NE</i>	<i>Norepinephrine</i>
<i>NO</i>	<i>Nitric oxide</i>
<i>NPA</i>	<i>Neuroprotective activity</i>
<i>NPY</i>	<i>Neuropeptide-Y</i>
<i>NS</i>	<i>Non significant</i>
<i>O₂⁻</i>	<i>Superoxide</i>
<i>OH•</i>	<i>Hydroxyl radical</i>
<i>PDH</i>	<i>Pyruvate dehydrogenase</i>
<i>PDHC</i>	<i>Pyruvate dehydrogenase complex</i>
<i>PFK</i>	<i>Phospho- fructokinase</i>
<i>PHT</i>	<i>Phenytoin</i>
<i>PTZ</i>	<i>Pentylentetrazol</i>
<i>PUFAs</i>	<i>Polyunsaturated fatty acids</i>
<i>RDA</i>	<i>Recommended Dietary Allowance</i>
<i>ROS</i>	<i>Reactive oxygen species</i>
<i>S</i>	<i>Significant</i>
<i>SCAD</i>	<i>Short-chain acyl dehydrogenase deficiency</i>
<i>SE</i>	<i>Selenium</i>
<i>SelP</i>	<i>Selenoprotein-P</i>
<i>SODs</i>	<i>Superoxide dismutases</i>
<i>SRS</i>	<i>Stereotactic radio-surgery</i>
<i>TAC</i>	<i>Total antioxidant capacity</i>
<i>TAS</i>	<i>Total Antioxidant Status</i>
<i>TBA</i>	<i>Thiobarbituric acid</i>
<i>TCA</i>	<i>Tricarboxylic acid</i>
<i>TR</i>	<i>Thioredoxin reductases</i>
<i>UCPs</i>	<i>Uncoupling proteins</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>UL</i>	<i>Upper Intake Level</i>
<i>VNS</i>	<i>Vagus nerve stimulation</i>
<i>VPA</i>	<i>Valproic acid</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

Epilepsy is a neurological illness characterized by tendency to generate epileptic seizures and by the neurological, psychological, cognitive, and social impacts of this condition. An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or hypersynchronous neuronal activity in the brain. This disturbance may cause strange sensations, emotions, and behavior, or generally convulsions, muscle spasms, and loss of consciousness (*Fisher et al., 2005*). There are many types of epileptic seizures that are specific to children, for example infantile spasms, Lennox-Gastaut syndrome and absence seizures.

Epilepsy may be burden affecting not less than 50 million patients worldwide (*Behr et al., 2016*). Children who suffer from epilepsy may develop other disorders and difficulties, preceding, co-occurring with, or after the diagnosis of epilepsy (*Aaberg et al., 2016*). It can also reduce quality of life (QoL) of patients (*Baker et al., 1997*), and may affect QoL of people caring for them as well.

Neuronal hyperexcitability and excessive production of free radicals have a major role in the pathogenesis of a considerable range of neurological disorders, including epilepsy. The high rate of oxidative metabolism, accompanied with the low antioxidant defenses and the increase in

polyunsaturated fatty acids, makes the brain highly vulnerable to free radical damage (*Devi et al., 2008*).

Although the overall prognosis for seizure control is good and over 70% will enter remission; about 25% of epilepsy is intractable and may need epilepsy surgery. However, up to 30% of patients undergoing presurgical evaluations eventually are not qualified for surgery (*Berg et al., 2003*) and face the prospect of ongoing seizures.

Intractable epilepsy according to International League Against Epilepsy (ILAE) is defined as a failure of adequate trials of 2 tolerated and appropriately chosen and used anti-epileptic drugs (AED) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom (*Kwan et al., 2010*).

Dietary therapies play a major role in management of epilepsy with other epilepsy treatments, such as anticonvulsant medications, epilepsy surgery, and vagus nerve stimulation. The ketogenic diet, which is very high in fat and low in carbohydrates, is thought to simulate the metabolic effects of starvation by forcing the body to use fat mainly as an energy source. During fasting, the body metabolizes fat stores through lipolysis to produce fatty acids which then undergo beta-oxidation into acetoacetate, β -hydroxybutyrate, and acetone—ketone bodies the brain cell can then use as precursors to generate adenosine triphosphate (ATP) (*Baraňano and*